Prof Henry Prince
Honorary (Professorial Fellow)
The Sir Peter MacCallum Department of Oncology
903 Scholarly works
11 Projects
HIGHLIGHTS
2026
Journal article
Occupational exposure to radiofrequency electromagnetic fields and risk of follicular lymphoma: Family case-control study
DOI: 10.1016/j.canep.2026.1032332026
Journal article
Early-Life Exposures and Risk of Multiple Myeloma: A Population-Based Case–Control Study in Australia
DOI: 10.1002/ijc.705392026
Journal article
Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial.
DOI: 10.1016/S1470-2045(26)00450-X2026
Journal article
Author reply.
DOI: 10.1111/imj.706412023
Research grants (ARC, NHMRC, MRFF)
Novel Approaches to the Treatment and Monitoring of Patients With Incurable Haematological Cancers
2018
Research Grant
Immunobiology and Immunotherapy of Cancer
2009
Journal article
Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure
DOI: 10.1200/JCO.2008.18.8573
RECENT SCHOLARLY WORKS
2026
Journal article
PA-185 Evaluation of Patient-Reported Outcomes and Subgroup Analysis With Subcutaneous Isatuximab Delivered via On-Body Injector Compared With Intravenous Delivery From the Phase 3 IRAKLIA Trial
DOI: 10.1016/s2152-2650(26)03552-42026
Journal article
PA-363 Premedication Use and Infusion-Related Reactions in Patients Treated With Subcutaneous Isatuximab: A Pooled Post Hoc Safety Analysis
DOI: 10.1016/s2152-2650(26)03726-22026
Journal article
OA-24 Etentamig Combined With Pomalidomide Plus Dexamethasone (Pom Dex) in Relapsed/Refractory Multiple Myeloma (RRMM) After 1–3 Prior Lines of Therapy: A Phase 1b Dose-Escalation and Safety Expansion Study
DOI: 10.1016/s2152-2650(26)03325-22026
Journal article
Perioperative ctDNA as a prognostic biomarker in endometrial cancer - the CODEC study
DOI: 10.1016/j.tranon.2026.1028712026
Journal article
PA-346 Phase 1/2, Open-Label, Platform Study of Surzetoclax with Etentamig in Biomarker-Selected Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
DOI: 10.1016/s2152-2650(26)03709-22026
Journal article
A Case of Primary Cutaneous BRAFV600E Langerhans Cell Histiocytosis, With Underlying Chronic Myelomonocytic Leukaemia, Responsive to Dabrafenib With Subsequent Undetectable Circulating Cell Free DNA
DOI: 10.1111/ajd.70143
RECENT PROJECTS
2014
Research Grant
Victorian Epigenetics Group (Veg): A Collaboration for Personalised Epigenetic Cancer Therapy Through Pre-Clinical Evaluation, Novel Biomarker Development and Early Phase Clinical Trials of New Drugs.
2015
Research Grant
Discovery of New Treatments for Therapy-Resistant Multiple Myeloma.